Phase 4 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a Schizophrenia Spectrum or Other Psychotic Disorder, confirmed using a standard diagnostic tool called the MINI
- People aged 18 or older
- Women who could become pregnant must be using a reliable form of contraception and must have a negative pregnancy test at the time of joining; male participants must not father a child during the study period
- People who are able to communicate in English
- People who are able to understand the study and provide written consent, as assessed using a standardised tool called the MacCAT-CR
- People who are living in the community (not hospitalised), taking a single oral antipsychotic medication — either risperidone (1–6mg), olanzapine (5–20mg), or paliperidone (3–12mg) — at the same dose for at least 3 months
- People who have been consistently taking their prescribed antipsychotic medication as directed
Who may not be able to join:
- People who have received a long-acting injectable (depot) antipsychotic within the past year
- People who currently have a substance use disorder as defined by standard diagnostic criteria, or who test positive for street drugs or non-prescribed medications
- People who have had electroconvulsive therapy (ECT) within the last 3 months
- People who are currently pregnant or breastfeeding
- People who have a neurological condition such as dementia, Alzheimer's disease, multiple sclerosis, epilepsy, stroke, or traumatic brain injury
- People who have a known allergy to any of the study medications or their ingredients
- People who have an allergy to lactose (such as galactosaemia) or a severe intolerance to lactose
- People whose urine drug test does not confirm the presence of their prescribed antipsychotic medication (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gary J Remington, MD, PhD, Centre for Addiction and Mental Health
Phone: 416-535-8501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical Deterioration using the "Brief Psychiatric Rating Scale - Expanded"
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.